Improving Ovarian Function in Women with Poor Ovarian Response Using Autologous Platelet-Rich Plasma Infusion A Randomized, Triple-Blind Phase 23 Study

What this Trial Is About

Researchers are evaluating the effects of autologous platelet-rich plasma PRP intra-ovarian infusion in women with poor ovarian response POR. This study is a triple-blind randomized controlled trial aiming to improve ovarian tissue function and outcomes of fresh embryo transfer in intracytoplasmic sperm injection ET-ICSI cycles. The study addresses the potential of PRP, which is rich in growth factors and cytokines, to stimulate tissue growth and ovarian rejuvenation in affected patients. Participants are assigned to one of two groups one receiving the autologous PRP intra-ovarian infusion, and the other receiving platelet-free plasma PFP as a placebo. Both groups undergo a fresh ET-ICSI cycle three months after the infusion during a follow-up period. The trial assesses the impact of these infusions on ovarian function and fertility treatment outcomes over time. Participants will be monitored monthly for three months following the infusion to evaluate hormonal levels, antral follicle count, and the number of oocytes retrieved after hCG administration. Clinical pregnancy rates are assessed 6 to 7 weeks after the last menstruation. The trial includes multiple evaluations such as hormonal profiles and ovarian imaging to measure changes. The total study duration extends until 2028, with primary outcome assessments occurring by January 2027.

Autologous Platelet-Rich Plasma Intra-ovarian Infusion in Poor Responders